A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Trial Profile

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Enzalutamide (Primary) ; Abiraterone acetate; Prednisone
  • Indications Bone metastases; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 19 Jun 2017 Planned number of patients changed from 270 to 470.
    • 30 May 2017 Planned End Date changed from 1 Jun 2021 to 8 Jul 2021.
    • 30 May 2017 Planned primary completion date changed from 1 Jun 2021 to 8 Jul 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top